RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
17 Ottobre 2024 - 3:15PM
(NASDAQ: RENB) – RenovaroCube, a leader in
AI-driven cancer diagnostics by integrating multi-omics with liquid
biopsies, is excited to announce the presentation of its latest
research at the Molecular Analysis for Precision Oncology Congress
– on October 16, 2024.
This study investigates the use of Oxford Nanopore sequencing on
circulating cell-free DNA (cfDNA) derived from blood plasma to
detect key copy number alterations (CNAs) in lung cancer patients.
CNAs are a key hallmark of cancer and can be used in cancer
monitoring, prognosis prediction, targeted therapy, and precise
cancer subtyping.
“The research demonstrates that Oxford Nanopore sequencing of
cell-free DNA from blood plasma can effectively capture significant
copy number alterations (CNAs), which characterize the copy number
landscape of lung cancer tissues—traditionally assessed through
tissue biopsy,” said Khashayar Roohollahi, senior scientist at
RenovaroCube.
Furthermore, CNAs can be used to estimate tumor fractions which
is useful for predicting cancer progression and monitoring. The
study emphasizes the potential of this technology in reducing the
need for invasive tissue biopsies, a significant advancement in
oncology.
Read more about the poster:
https://renovarogroup.com/novel-insights-on-non-invasive-cancer-diagnostics-poster/
RenovaroCube remains committed to advancing precision medicine
through innovative research and technologies, offering hope for
more effective, patient-centered cancer care.
About RenovaroRenovaro https://renovarogroup.com/ aims
to accelerate precision and personalized medicine for longevity
powered by mutually reinforcing AI and biotechnology platforms for
early diagnosis, better-targeted treatments, and drug discovery.
Renovaro Inc. includes RenovaroBio with its advanced cell-gene
immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is
committed to the early detection of cancer and its recurrence and
monitoring subsequent treatments utilizing non-invasive liquid
biobsy. RenovaroCube intervenes at a stage where potential therapy
can be most effective. RenovaroCube is a molecular data science
company with a background in FinTech and a 12-year history. It
brings together proprietary artificial intelligence (AI)
technology, multi-omics, multi-modal data, and the expertise of a
carefully selected multidisciplinary team to radically accelerate
precision medicine and enable breakthrough changes in disease
agnostic decision support.
About MAPMAP focuses on current and emerging
approaches in precision oncology, highlights successes and
challenges, and proposes potential solutions in clinical research
and practice.
Forward-Looking StatementsStatements in this
press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties, including but not limited to the
success or efficacy of our pipeline, platform and fundraising. All
statements other than historical facts are forward-looking
statements, which can be identified by the use of forward-looking
terminology such as “believes,” “plans,” “expects,” “aims,”
“intends,” “potential,” or similar expressions. Actual events or
results may differ materially from those projected in any of such
statements due to various uncertainties, including as set forth in
Renovaro’s most recent Annual Report on Form 10-K filed with the
SEC. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Renovaro Inc. undertakes
no obligation to revise or update this press release to reflect
events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com and
STarsh@Renovarogroup.com
Source: Renovaro Inc.
Grafico Azioni Renovaro (NASDAQ:RENB)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Renovaro (NASDAQ:RENB)
Storico
Da Gen 2024 a Gen 2025